Circadian Phase Assessments at Home

Sponsor
Rush University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT01487252
Collaborator
National Center for Complementary and Integrative Health (NCCIH) (NIH)
73
1
2
41
1.8

Study Details

Study Description

Brief Summary

An estimated 23 million Americans, including adolescents and the elderly, suffer from circadian rhythm sleep disorders, such as delayed sleep phase disorder, advanced sleep phase disorder and winter depression. These conditions are characterized by persistent insomnia and/or excessive daytime sleepiness, impaired performance, reduced well being and lower quality of life. The negative symptoms result from a misalignment between the timing of sleep and the internal circadian clock. Clinical research has demonstrated that circadian rhythm sleep disorders are most effectively diagnosed (differentiated from other causes of insomnia) and treated if each individual patient's circadian phase is known. The timing of the master internal circadian clock is most reliably measured from the onset of the endogenous circadian rhythm of melatonin, a neuroendocrine hormone, as measured in dim light (dim light melatonin onset, or "DLMO"). However to date the reliable and valid assessment of the DLMO is limited to the research laboratory setting.

This study is to test a streamlined procedure for the accurate assessment of circadian phase (DLMO) outside of the laboratory that will provide clinicians and researchers with a novel diagnostic and research tool. In this way the underlying neurobiological cause of a patient's insomnia and/or circadian rhythm disorder can more readily be diagnosed and treated.

Specific Aim 1 is to validate procedures for at-home circadian phase assessment in a sample of healthy people. Validation will occur by (1) objectively measuring compliance to the at-home procedures and (2) comparing DLMOs collected at home to DLMOs collected in the laboratory, in a within-subjects counterbalanced design. Specific Aim 2 is to validate the same at home procedures in patients with delayed sleep phase disorder. Specific Aim 3 is to conduct rigorous analyses to inform future users which subject characteristics and light levels predict (1) compliance to the at home procedures and (2) valid at-home DLMOs.

The results of this 3 year study will have substantial implications for the translation of basic and clinical research to the community: (1) the diagnosis and treatment of insomnia and circadian rhythm sleep disorders will be significantly enhanced, thus improving public health and safety, mood and quality of life, (2) community participation in research will be improved, particularly in vulnerable and under represented populations, thus increasing scientific knowledge and (3) research and clinical costs will be substantially reduced.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: At home saliva sampling
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
73 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Study Start Date :
Dec 1, 2011
Actual Primary Completion Date :
Dec 1, 2014
Actual Study Completion Date :
May 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Healthy Controls

Behavioral: At home saliva sampling
Saliva samples taken every half an hour in evening before bedtime.

Active Comparator: Delayed Sleep Phase Disorder

Behavioral: At home saliva sampling
Saliva samples taken every half an hour in evening before bedtime.

Outcome Measures

Primary Outcome Measures

  1. Dim Light Melatonin Onset [9 days]

    The DLMO is assessed twice at home and twice in the laboratory.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 69 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy adult volunteers or people with Delayed Sleep Phase Disorder
Exclusion Criteria:
  • Color blindness with the Ishihara test

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rush University Medical Center Chicago Illinois United States 60612

Sponsors and Collaborators

  • Rush University Medical Center
  • National Center for Complementary and Integrative Health (NCCIH)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Helen Burgess, Professor, Rush University Medical Center
ClinicalTrials.gov Identifier:
NCT01487252
Other Study ID Numbers:
  • AT007104
First Posted:
Dec 7, 2011
Last Update Posted:
Apr 12, 2017
Last Verified:
Apr 1, 2017

Study Results

No Results Posted as of Apr 12, 2017